| 摘要 |
<p>PROBLEM TO BE SOLVED: To provide a therapeutic agent for psychiatric diseases or neurodegenerative diseases related to mGluR5 and MAO-B, having both of effects as a metabolism type glutamic acid receptor subtype 5 (mGluR5) negative modulator and MAO-B inhibitory activity, pharmacokinetically excellent oral absorptivity, high in bioavailability and excellent in safety.SOLUTION: There is provided a compound of the formula (I) or pharmaceutically acceptable salt thereof. (I), where R represents hydrogen, halogen, Calkyl or cyano.</p> |
